Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Alessandra Baldoni et al.|The Lancet Oncology|2021Cited by 412
Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the footFlorian Scotté, Stéphane Oudard, Jacques Médioni et al.|Cancer|2008Cited by 104
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).Michele Maio, Tibor Csőszi, Michael Schenker et al.|Journal of Clinical Oncology|2021Cited by 7